Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(10), P. 2250 - 2250
Published: Oct. 3, 2024
T-cell-based
adoptive
cell
therapies
have
emerged
at
the
forefront
of
cancer
immunotherapies;
however,
failed
long-term
survival
and
inevitable
exhaustion
transplanted
T
lymphocytes
in
vivo
limits
clinical
efficacy.
Leukemia
blasts
possess
enhanced
glycolysis
(Warburg
effect),
exploiting
their
microenvironment
to
deprive
nutrients
(e.g.,
glucose)
from
cells,
leading
T-cell
dysfunction
leukemia
progression.
Experimental Hematology and Oncology,
Journal Year:
2024,
Volume and Issue:
13(1)
Published: Dec. 4, 2024
Abstract
Immunotherapy
has
transformed
the
landscape
of
cancer
treatment,
with
chimeric
antigen
receptor
(CAR)-engineered
T
(CAR-T)
cell
therapy
emerging
as
a
front
runner
in
addressing
some
hematological
malignancies.
Despite
its
considerable
efficacy,
occurrence
severe
adverse
effects
associated
CAR-T
limited
their
scope
and
prompted
exploration
alternative
therapeutic
strategies.
Natural
killer
(NK)
cells,
characterized
by
both
innate
cytotoxicity
ability
to
lyse
target
cells
without
constraint
peptide
specificity
conferred
major
histocompatibility
complex
(MHC),
have
similarly
garnered
attention
viable
immunotherapy.
As
such,
another
approach
recently
emerged
that
seeks
combine
continued
success
flexibility
NK
cells.
Clinical
trials
involving
CAR-engineered
(CAR-NK)
exhibited
promising
efficacy
fewer
deleterious
side
effects.
This
review
aims
provide
concise
overview
cellular
molecular
basis
biology,
facilitating
better
understanding
advancements
CAR
design
manufacturing.
The
focus
is
on
current
approaches
strategies
employed
CAR-NK
development,
exploring
at
preclinical
clinical
settings.
We
will
reflect
upon
achievements,
advantages,
challenges
intrinsic
therapy.
Anticipating
maturation
technology,
we
foresee
encouraging
prospects
for
broader
range
patients
other
conditions.
It
our
belief
this
progress
bring
us
closer
making
significant
strides
treatment
refractory
recurrent
cancers,
well
immune-mediated
disorders.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 22, 2024
SUMMARY
Adoptive
cell
therapies
(ACT)
using
unmodified
or
engineered
invariant
Natural
Killer
T
(iNKT)
cells
are
in
clinical
trials
for
cancer
treatment.
While
promising,
outcomes
still
suboptimal,
possibly
due
to
iNKT
heterogeneity.
This
study
identified
unique
populations
with
strong
cytotoxic
activity
mice
and
humans.
In
mice,
iNKT1c
showed
potent
CD1d-dependent
-independent
antitumor
functions,
responses
influenced
by
NK
receptors.
IL-15
enhances
their
cytolytic
activity,
while
retinoic
acid
is
essential
generation.
humans,
terminally
differentiated
CD57
+
marked
NK-receptor
expression
most
effectively
killed
C1R
tumor
vitro
.
These
appeared
activated/exhausted
within
tumors
of
non-small
lung
patients.
Additionally,
a
central
memory-like
CD62L
CD4
-
subset
efficiently
expanded
generated
,
making
them
an
appealing
candidate
ACT.
paves
the
way
design
more
effective
cell-based
immunotherapies.
ImmunoTargets and Therapy,
Journal Year:
2024,
Volume and Issue:
Volume 13, P. 413 - 433
Published: Aug. 1, 2024
The
CAR-T
cell
therapy
has
marked
the
dawn
of
new
era
in
cancer
therapeutics
and
engineering
techniques.
review
emphasizes
on
challenges
that
obstruct
therapeutic
efficiency
caused
by
toxicities,
immunosuppressive
tumor
environment,
decreased
T
infiltration.
In
interest
achieving
overall
survival
(OS)
event-free
(EFS)
patients,
conceptual
background
potential
target
selection
various
design
techniques
are
described
which
can
minimize
off-target
effects,
reduce
toxicity,
thus
increase
resilience
treatment
haematological
malignancies
as
well
solid
tumors.
Furthermore,
it
delves
into
cutting-edge
technologies
like
gene
editing
synthetic
biology,
providing
opportunities
to
enhance
functionality
cells
overcome
mechanisms
immune
evasion.
This
provides
a
comprehensive
understanding
complex
diverse
aspects
cell-based
treatments,
including
both
scientific
clinical
aspects.
By
effectively
addressing
obstacles
utilizing
capabilities
technology,
shows
fundamentally
changing
immunotherapy
reshaping
approach
treatment.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(10), P. 2250 - 2250
Published: Oct. 3, 2024
T-cell-based
adoptive
cell
therapies
have
emerged
at
the
forefront
of
cancer
immunotherapies;
however,
failed
long-term
survival
and
inevitable
exhaustion
transplanted
T
lymphocytes
in
vivo
limits
clinical
efficacy.
Leukemia
blasts
possess
enhanced
glycolysis
(Warburg
effect),
exploiting
their
microenvironment
to
deprive
nutrients
(e.g.,
glucose)
from
cells,
leading
T-cell
dysfunction
leukemia
progression.
